Company News

Share this article:
Gilead Sciences closing two cardiovascular-focused research and development offices in Colorado. The closures stem from Gilead's acquisition of California-based CV Therapeutics, according to an Associated Press report. A spokesperson for Gilead said the company is consolidating its operations in California.

AstraZeneca partnered with Forest Laboratories for the development and commercialization of ceftaroline, an experimental antibiotic. The partnership includes markets outside of the US, Canada and Japan. Financial terms of the deal were not disclosed.   

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.